vs
Side-by-side financial comparison of American Homes 4 Rent (AMH) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
American Homes 4 Rent is the larger business by last-quarter revenue ($455.0M vs $339.0M, roughly 1.3× HAEMONETICS CORP). American Homes 4 Rent runs the higher net margin — 31.7% vs 13.2%, a 18.5% gap on every dollar of revenue. On growth, American Homes 4 Rent posted the faster year-over-year revenue change (4.2% vs -2.7%). American Homes 4 Rent produced more free cash flow last quarter ($823.7M vs $87.2M). Over the past eight quarters, American Homes 4 Rent's revenue compounded faster (3.6% CAGR vs 0.4%).
American Homes 4 RentAMHEarnings & Financial Report
American Homes 4 Rent, doing business as AMH, is a real estate investment trust based in Las Vegas, Nevada, that invests in single-family rental homes. As of December 31, 2019, the company owned 52,552 homes in 22 states. Its largest concentrations are in Atlanta, Dallas-Fort Worth, and Charlotte, North Carolina.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
AMH vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $455.0M | $339.0M |
| Net Profit | $144.3M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | — | 19.9% |
| Net Margin | 31.7% | 13.2% |
| Revenue YoY | 4.2% | -2.7% |
| Net Profit YoY | 0.3% | 19.3% |
| EPS (diluted) | $0.33 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $455.0M | $339.0M | ||
| Q3 25 | $478.5M | $327.3M | ||
| Q2 25 | $457.5M | $321.4M | ||
| Q1 25 | $459.3M | $330.6M | ||
| Q4 24 | $436.6M | $348.5M | ||
| Q3 24 | $445.1M | $345.5M | ||
| Q2 24 | $423.5M | $336.2M | ||
| Q1 24 | $423.6M | — |
| Q4 25 | $144.3M | $44.7M | ||
| Q3 25 | $116.8M | $38.7M | ||
| Q2 25 | $123.6M | $34.0M | ||
| Q1 25 | $128.7M | $58.0M | ||
| Q4 24 | $143.9M | $37.5M | ||
| Q3 24 | $87.6M | $33.8M | ||
| Q2 24 | $108.5M | $38.4M | ||
| Q1 24 | $128.1M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | — | 16.8% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 15.0% | ||
| Q2 24 | — | 11.8% | ||
| Q1 24 | — | — |
| Q4 25 | 31.7% | 13.2% | ||
| Q3 25 | 24.4% | 11.8% | ||
| Q2 25 | 27.0% | 10.6% | ||
| Q1 25 | 28.0% | 17.5% | ||
| Q4 24 | 33.0% | 10.8% | ||
| Q3 24 | 19.7% | 9.8% | ||
| Q2 24 | 25.6% | 11.4% | ||
| Q1 24 | 30.2% | — |
| Q4 25 | $0.33 | $0.95 | ||
| Q3 25 | $0.27 | $0.81 | ||
| Q2 25 | $0.28 | $0.70 | ||
| Q1 25 | $0.30 | $1.17 | ||
| Q4 24 | $0.33 | $0.74 | ||
| Q3 24 | $0.20 | $0.66 | ||
| Q2 24 | $0.25 | $0.74 | ||
| Q1 24 | $0.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.5M | $363.4M |
| Total DebtLower is stronger | $5.1B | $1.2B |
| Stockholders' EquityBook value | $7.0B | $911.5M |
| Total Assets | $13.2B | $2.5B |
| Debt / EquityLower = less leverage | 0.72× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.5M | $363.4M | ||
| Q3 25 | $45.6M | $296.4M | ||
| Q2 25 | $323.3M | $292.9M | ||
| Q1 25 | $69.7M | $306.8M | ||
| Q4 24 | $199.4M | $320.8M | ||
| Q3 24 | $162.5M | $299.3M | ||
| Q2 24 | $718.4M | $344.4M | ||
| Q1 24 | $124.8M | — |
| Q4 25 | $5.1B | $1.2B | ||
| Q3 25 | $4.8B | $1.2B | ||
| Q2 25 | $5.2B | $1.2B | ||
| Q1 25 | $4.9B | $1.2B | ||
| Q4 24 | $5.0B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $5.0B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $7.0B | $911.5M | ||
| Q3 25 | $7.2B | $849.2M | ||
| Q2 25 | $7.2B | $882.3M | ||
| Q1 25 | $7.2B | $820.8M | ||
| Q4 24 | $7.2B | $906.9M | ||
| Q3 24 | $7.0B | $878.9M | ||
| Q2 24 | $7.0B | $905.4M | ||
| Q1 24 | $7.0B | — |
| Q4 25 | $13.2B | $2.5B | ||
| Q3 25 | $13.3B | $2.4B | ||
| Q2 25 | $13.6B | $2.5B | ||
| Q1 25 | $13.3B | $2.5B | ||
| Q4 24 | $13.4B | $2.5B | ||
| Q3 24 | $12.8B | $2.5B | ||
| Q2 24 | $13.3B | $2.5B | ||
| Q1 24 | $12.8B | — |
| Q4 25 | 0.72× | 1.34× | ||
| Q3 25 | 0.68× | 1.44× | ||
| Q2 25 | 0.72× | 1.39× | ||
| Q1 25 | 0.69× | 1.49× | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.64× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $864.3M | $93.6M |
| Free Cash FlowOCF − Capex | $823.7M | $87.2M |
| FCF MarginFCF / Revenue | 181.0% | 25.7% |
| Capex IntensityCapex / Revenue | 8.9% | 1.9% |
| Cash ConversionOCF / Net Profit | 5.99× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $864.3M | $93.6M | ||
| Q3 25 | $223.3M | $111.3M | ||
| Q2 25 | $271.9M | $17.4M | ||
| Q1 25 | $223.4M | $116.6M | ||
| Q4 24 | $811.5M | $43.8M | ||
| Q3 24 | $233.6M | $48.8M | ||
| Q2 24 | $274.0M | $-27.4M | ||
| Q1 24 | $201.8M | — |
| Q4 25 | $823.7M | $87.2M | ||
| Q3 25 | $214.5M | $106.3M | ||
| Q2 25 | $257.7M | $13.6M | ||
| Q1 25 | $215.9M | $100.9M | ||
| Q4 24 | $777.5M | $35.2M | ||
| Q3 24 | $225.3M | $39.4M | ||
| Q2 24 | $263.3M | $-33.1M | ||
| Q1 24 | $191.0M | — |
| Q4 25 | 181.0% | 25.7% | ||
| Q3 25 | 44.8% | 32.5% | ||
| Q2 25 | 56.3% | 4.2% | ||
| Q1 25 | 47.0% | 30.5% | ||
| Q4 24 | 178.1% | 10.1% | ||
| Q3 24 | 50.6% | 11.4% | ||
| Q2 24 | 62.2% | -9.8% | ||
| Q1 24 | 45.1% | — |
| Q4 25 | 8.9% | 1.9% | ||
| Q3 25 | 1.8% | 1.5% | ||
| Q2 25 | 3.1% | 1.2% | ||
| Q1 25 | 1.6% | 4.7% | ||
| Q4 24 | 7.8% | 2.5% | ||
| Q3 24 | 1.9% | 2.7% | ||
| Q2 24 | 2.5% | 1.7% | ||
| Q1 24 | 2.6% | — |
| Q4 25 | 5.99× | 2.09× | ||
| Q3 25 | 1.91× | 2.88× | ||
| Q2 25 | 2.20× | 0.51× | ||
| Q1 25 | 1.74× | 2.01× | ||
| Q4 24 | 5.64× | 1.17× | ||
| Q3 24 | 2.67× | 1.44× | ||
| Q2 24 | 2.52× | -0.71× | ||
| Q1 24 | 1.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMH
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
